bullet point to $69 million) * Says taking Q3 $69 million charge for investment losses, including in Lehman, Washington Mutual * Says enrollment in some European bapineuzumab trials delayed as regulators review phase 2 data, phase 3 trial designs * Says...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to CORRECTED-BRIEF-Wyeth cites losses in Lehman, Washington Mutual
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account